ArticleClinical genitourinary cancer2017
Prostate Cancer Patients With Unmanaged Diabetes or Receiving Insulin Experience Inferior Outcomes and Toxicities After Treatment With Radiation Therapy.
Article in Clinical genitourinary cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 4 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Influence of Diabetes Mellitus on Oncological Outcomes for Patients Living With Cancer.The science of diabetes self-management and care · 2023Pooled it
- The effect of metformin therapy on incidence and prognosis in prostate cancer: A systematic review and meta-analysis.Scientific reports · 2019Pooled it
- Skin CanceR Brachytherapy vs External beam radiation therapy (SCRiBE) meta-analysis.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2018Pooled it
- Hypofractionated radiation therapy for basal and squamous cell skin cancer: A meta-analysis.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2017Pooled it
- Assessing the Feasibility of a Self-Management Intervention for Individuals With Advanced Prostate Cancer and Comorbid Type II Diabetes Mellitus.Cancer medicine · 2026Trial
- Change in Adherence to Oral Antidiabetic Medications Before and After Prostate Cancer Diagnosis: A Group-Based Trajectory Modeling Approach.Clinical drug investigation · 2026Article
- Safety of carbon-ion radiotherapy for prostate cancer after rectal surgery: a single-institution retrospective study.Journal of radiation research · 2026Article
- Unplanned hospitalization among advanced prostate cancer patients by diabetes status: a population-based study.JNCI cancer spectrum · 2025Article
- Racial disparities in the receipt of therapies for cancer, hypertension, and diabetes, and in mortality in a large population-based cohort of older men with prostate cancer.Ethnicity & health · 2025Article
- Evaluating the Impact of Common Non-Oncologic Medication Use During Radiotherapy in Patients with High-Risk Prostate Cancer.Current oncology (Toronto, Ont.) · 2025Article
- The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer.Molecular cancer · 2025Article
- A Problem in NIH and Federally Funded Prostate Cancer Interventional Clinical Trials.Journal of racial and ethnic health disparities · 2024Article
- The association of diabetes mellitus and routinely collected patient-reported outcomes in patients with cancer. A real-world cohort study.Cancer medicine · 2024Article
- Diabetes and Prostate Cancer Outcomes in Men with Nonmetastatic Castration-Resistant Prostate Cancer: Results from the SEARCH Cohort.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
- Diabetes and skin cancers: Risk factors, molecular mechanisms and impact on prognosis.World journal of clinical cases · 2022Review
- Review
- Article
- Salvage therapy for prostate cancer after radical prostatectomy.Nature reviews. Urology · 2021Review
- Effects of diabetes on the development of radiation pneumonitis.Respiratory research · 2021Review
- Understanding the Prevalence of Prediabetes and Diabetes in Patients With Cancer in Clinical Practice: A Real-World Cohort Study.Journal of the National Comprehensive Cancer Network : JNCCN · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe purpose of the study was to determine the effect of type 2 diabetes mellitus (T2DM) on outcomes and toxicities among men with localized prostate cancer receiving definitive radiation therapy. PATIENTS AND
methodsWe performed a retrospective review of 3217 patients, from 1998 to 2013, subdivided into 5 subgroups: (I) no T2DM; (II) T2DM receiving oral antihyperglycemic agent that contains metformin, no insulin; (III) T2DM receiving nonmetformin oral agent alone, no insulin; (IV) T2DM receiving any insulin; and (V) T2DM not receiving medication. Outcome measures were overall survival, freedom from biochemical failure (BF), freedom from distant metastasis, cancer-specific survival, and toxicities. Kaplan-Meier analysis, log rank tests, Fine and Gray competing risk regression (to adjust for patient and lifestyle factors), Cox models, and subdistribution hazard ratios (sHRs) were used.
resultsOf the 3217 patients, 1295 (40%) were low-risk, 1192 (37%) were intermediate-risk, and 652 (20%) were high risk. The group I to V distribution was 81%, 8%, 5%, 3%, and 4%. The median dose was 78 Gy, and the median follow-up time was 50 (range, 1-190) months. Group V had increased mortality (sHR, 2.1; 95% confidence interval [CI], 0.66-1.54), BF (sHR, 2.14; 0.88-1.83), and cause-specific mortality (sHR, 3.87; 95% CI, 1.31-11). Acute toxicities were higher in group IV versus group I (genitourinary: 38% vs. 26%; P = .01; gastrointestinal: 21% vs. 5%; P = 001). Late toxicities were higher in groups IV and V versus group I (12%-14% vs. 2%-6%; P < .01).
conclusionMen with T2DM not receiving medication and men with T2DM receiving insulin had worse outcomes and toxicities compared to other patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.